Pharmaceutical

Five things for pharma marketers to know: Friday, May 22

Five things for pharma marketers to know: Friday, May 22

Amgen's PSCK9 inhibitor gets a position opinion in the EU; the FDA plans to study how spouses influence perception of DTC ads; Botox may relieve depression

OPDP finds fault with Rapaflo website

The FDA's advertising division said images and copy for the BPH drug Rapaflo are misleading.

Five things for pharma marketers to know: Thursday, May 21

Five things for pharma marketers to know: Thursday, May 21

CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year

Banner triggers OPDP letter to Oak Pharmaceuticals

The FDA's bad-ad group said the banner they saw at a professional conference was misleading.

Torres: Career challenges prepared her to take reins at McNeil

Torres: Career challenges prepared her to take reins at McNeil

McNeil Consumer Healthcare president Denice Torres was named woman of the year by the Healthcare Businesswomen's Association.

Five things for pharma marketers to know: Tuesday, May 19

Five things for pharma marketers to know: Tuesday, May 19

Perrigo says a Mylan deal is possible; new guidelines may reduce cancer screenings; Takeda petitions dictionaries to add a new definition for depression

Inhaled insulin stymied by drive for value

Inhaled insulin stymied by drive for value

Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.

Five things for pharma marketers to know: Monday, May 18

Five things for pharma marketers to know: Monday, May 18

Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition

Makovsky's head of health moving to Finn Partners

Makovsky's head of health moving to Finn Partners

Long-time practice lead Gil Bashe is tasked with unifying and building the health function at global firm Finn Partners.

Five things for pharma marketers to know: Friday, May 15

Five things for pharma marketers to know: Friday, May 15

Genentech alums launch a new biotechnology company; Mallinckrodt sues the FDA over a drug reclassification; Sanofi takes on celiac disease